Brian Daniel Webster - 17 Aug 2026 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Reporting relationship: President and Chief Executive Officer, Director
Issuer ticker: KMTS
Reported as of: 17 Aug 2026
Net transaction value: -$412,180
SEC form: 4
Accepted by SEC: 18 Aug 2026, 19:01:32 UTC
Prior SEC filing: 06 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Brian Daniel Webster

Key filing fact

Brian Daniel Webster filed Form 4 for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on 18 Aug 2026.

Key facts

This page summarizes Brian Daniel Webster's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 19:01.

Change

Previous filing in this sequence was filed on 06 Aug 2026.
Current net transaction value: -$412,180.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877188 Primary reporting owner

Webster Brian Daniel

Relationship: President and Chief Executive Officer, Director
Address: 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND
Signature: /s/ Brian Daniel Webster
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KMTS transaction

Common Shares

Sale

Transaction value: $412,180
Shares: -15,000
Change %: -3.2%
Price: $27.48
Shares after: 460,215
Date: 17 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

Footnote F2

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.9200 to $27.7700. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

SEC remarks

President and Chief Executive Officer